Based on our observations that ActivinA boosts B-ALL vesiculation and that B-ALL-derived EVs promote survival in a dose-dependent manner, we can hypothesize that the increased number of EV-ActA could be responsible of the superior viability of EV-ActA-treated B-ALL cells. This evidence concerns the gene ACTA1 and acute lymphoblastic leukemia.